Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Earnings for Singular Genomics Systems, Inc. (OMIC)
Earnings in 2023 (TTM): $-94,820,000
According to Singular Genomics Systems, Inc.'s latest financial reports the company's current earnings (TTM) are $-94,820,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Singular Genomics Systems, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-94,820,000 | $-94,820,000 |
| 2022 | $-90,879,000 | $-88,271,000 |
| 2021 | $-98,771,000 | $-98,889,000 |
| 2020 | $-27,945,000 | $-28,663,000 |
| 2019 | $-12,324,000 | $-12,341,000 |